85 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
and assumptions concerning:
the availability of capital on acceptable terms to fund planned expenditures;
prevailing regulatory, tax and environmental … tax credits from the Canadian government in order to further our research and development. Although it is difficult to predict our funding requirements
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
include:
the availability of capital to fund planned expenditures;
prevailing regulatory, tax and environmental laws and regulations;
the ability … and regulations which alter tax rates and/or capital allowances could have a material adverse impact on us. To the extent that revenues and expenditures
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
the Company nor any Subsidiary is in default with respect to any Indebtedness.
(ff) Tax Status. Except for matters that would not, individually … United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
planned expenditures;
prevailing regulatory, tax and environmental laws and regulations; and
the ability to secure necessary personnel, equipment … to continue our efforts to pursue additional grants and refundable tax credits from the Canadian government in order to further our research
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
and assumptions concerning:
the availability of capital on acceptable terms to fund planned expenditures;
prevailing regulatory, tax and environmental … tax credits from the Canadian government in order to further our research and development. Although it is difficult to predict our funding
424B3
v0q400gh9hzuezplgcu
13 Jun 24
Prospectus supplement
4:11pm
424B3
tr1d nnskl
13 Jun 24
Prospectus supplement
4:10pm
424B3
pd8o8ywvqmjn01415o
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
940gbj mt1xqdh
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
rgdomi39vi52 q38
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
93wp6d
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
r5rsxs0an5 9pdtz8ocp
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
kz77h
25 Aug 23
Prospectus supplement
6:00am
424B3
gbi u7qrr3
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
47yq m5ev6kn8t
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
njict8 i5ib7c5z1n
14 Aug 23
Prospectus supplement
4:42pm